This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for 2025.
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2025.
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2025.
Report Scope
- The 2025 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.
Reasons to Buy
This report will enable the user to answer the following questions:
- What are the trends by region, therapy area, sites by CROs for the past year?
- Who was the most active CRO in the past quarter?
- Who were the most active sponsors by market cap in the past year?
- What was the most widely studied therapy area in the past year vs. the previous year?
- By region, who had the most clinical trials initiated in the past year?
- By region, what were the Q4 2025 CRO invitations and appointments?
Table of Contents
- About the Analyst
- Introduction
- Global
- CRO and sponsor activity in 2025
- Clinical trials in oncology and CNS
- North America
- Clinical trial activity in North America in 2025
- Europe
- Clinical trial activity in Europe in 2025
- Rest of the World
- Clinical trial activity in ROW in 2025
- Appendix
- Authors and Editorial Team
- Contact the Publisher
- Disclaimer
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- IQVIA
- ICON
- PPD
- Clario
- Labcorp Drug Development
- Parexel
- Syneos
- Fortrea
- Signant Health Management
- WCG Clinical
- AstraZeneca
- Merck
- Novartis
- Pfizer
- Eli Lilly
- Jiangsu Hengrui Pharmaceuticals
- CSPC Pharmaceutical Group
- AbbVie
- Sanofi
- Bristol Myers Squibb
- Haisco Pharmaceutical Group
- Zhejiang Huahai Pharmaceutical
- Zydus Lifesciences
- Gan & Lee Pharmaceuticals
- Shanghai Henlius Biotech
- Apeloa Pharmaceutical
- Jiangsu Nhwa Pharmaceutical
- Huadong Medicine
- KeyMed Biosciences
- Sichuan Kelun Pharmaceutical
- Beijing Foyou Pharma
- Boryung
- Sinovac Biotech
- Cisen Pharmaceutical
- Daewoong
- Chong Kun Dang Holdings
- Daewoong Pharmaceutical
- Dong-A ST
- Tianjin Lisheng Pharmaceutical
- Akebia Therapeutics
